Landos Biopharma, Inc. - LABP
About Gravity Analytica
Recent News
- 06.08.2026 - AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- 06.02.2026 - AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- 06.02.2026 - AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
- 05.29.2026 - AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- 05.27.2026 - U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- 05.22.2026 - AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- 05.21.2026 - AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- 05.21.2026 - Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
- 05.06.2026 - AbbVie to Present at the Bank of America Securities Healthcare Conference
- 05.05.2026 - AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®